Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
Sign Up to like & getrecommendations! Published in 2023 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s392155
Abstract: Purpose Biological therapies targeting eosinophils have been shown to be effective in treating patients with severe eosinophilic asthma. Benralizumab (Fasenra®, AstraZeneca) is a humanized monoclonal antibody binding to the alpha subunit of the interleukin-5 receptor,… read more here.
Keywords: pharmacokinetics benralizumab; safety; chinese participants; healthy chinese ... See more keywords